AJMC® in the Press, April 5, 2024

Frequent Primary Care Visits May Lower Costs for Higher-Risk Commercially Insured Adults

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

Blood-Based Biomarkers Could Reshape Soft Tissue Sarcoma Therapy

Tory M. Wolff, MBA, discusses his study showing that frequent routine primary care visits may lower costs for higher-risk commercially insured adults.

Listen

The authors said blood-based biomarkers for ICI response should be a research priority in soft tissue sarcoma moving forward. | Image credit: Dzmitry - stock.adobe.com

Dr Anders Kolb on Leading Blood Cancer United Into a New Era

Biomarkers like neutrophil-to-lymphocyte ratio could help predict treatment response to immune checkpoint inhibitors in certain patients with soft tissue sarcoma.

September 25th 2025

FDA Approves Remibrutinib for Chronic Spontaneous Urticaria

Blood Cancer United, formerly Leukemia & Lymphoma Society, aims to enhance awareness and support for blood cancer patients during Blood Cancer Awareness Month.

Listen

The approval was supported by data from the phase 3 REMIX-1 and REMIX-2 clinical trials. | Image credit: wladimir1804 - stock.adobe.com

Immune Signatures Linked to Treatment Response, Outcomes in Critical Illness

The approval of remibrutinib for patients with chronic spontaneous urticaria was supported by data from the phase 3 REMIX-1 and REMIX-2 clinical trials.

Doctor talking to patient and family | Image credit: DC Studio – stock.adobe.com

Weighing Osimertinib vs Amivantamab-Lazertinib in Frontline EGFR NSCLC: Danny Nguyen, MD

Immune gene signatures were linked to illness severity and treatment response in sepsis and other critical conditions.

Related Content

October 1st 2025

Frequent Primary Care Visits May Lower Costs for Higher-Risk Commercially Insured Adults

Amivantamab plus lazertinib enhances survival in NSCLC but requires complex care compared with osimertinib, explained Danny Nguyen, MD, of City of Hope.

Blood-Based Biomarkers Could Reshape Soft Tissue Sarcoma Therapy

Tory M. Wolff, MBA, discusses his study showing that frequent routine primary care visits may lower costs for higher-risk commercially insured adults.

Listen

Dr Anders Kolb on Leading Blood Cancer United Into a New Era

Biomarkers like neutrophil-to-lymphocyte ratio could help predict treatment response to immune checkpoint inhibitors in certain patients with soft tissue sarcoma.

September 25th 2025

FDA Approves Remibrutinib for Chronic Spontaneous Urticaria

Blood Cancer United, formerly Leukemia & Lymphoma Society, aims to enhance awareness and support for blood cancer patients during Blood Cancer Awareness Month.

Listen

Immune Signatures Linked to Treatment Response, Outcomes in Critical Illness

The approval of remibrutinib for patients with chronic spontaneous urticaria was supported by data from the phase 3 REMIX-1 and REMIX-2 clinical trials.